Celltrion (KRX:068270) agreed to acquire Eli Lilly's manufacturing facility in New Jersey for 700 billion won, which included operating funds, to cushion the impact from US tariffs, the South Korean biopharmaceutical company said Tuesday.

The manufacturing facilities comprise four buildings on a site spread across 45,000 pyeong.

Celltrion expects immediate operational readiness, reduced contract manufacturing organization (CMO) and logistics costs, and early return on investment through existing CMO contracts and full employment succession.

The acquisition is scheduled for completion by end-2025, pending US regulatory approvals.

Shares of Celltrion jumped nearly 9% at market close.